Kezar Life Sciences, Inc. (KZR)
| Market Cap | 672.82M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -51.36M |
| Shares Out | 49.15M |
| EPS (ttm) | -1.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,137,817 |
| Open | 12.84 |
| Previous Close | 13.24 |
| Day's Range | 12.99 - 13.77 |
| 52-Week Range | 4.61 - 14.35 |
| Beta | 0.27 |
| Analysts | Strong Buy |
| Price Target | 20.00 (+46.1%) |
| Earnings Date | Nov 4, 2021 |
About KZR
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products includ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for KZR stock is "Strong Buy." The 12-month stock price forecast is 20.00, which is an increase of 46.09% from the latest price.
News
Why Kezar Life Sciences Stock Is Soaring Today
The company reported promising results from a phase 2 study.
Small-cap Biopharma Kezar Life Sciences Is Soaring, Here's Why
Kezar Life Sciences, Inc. (NASDAQ: KZR) shares are soaring Tuesday following a positive clinical readout. What Happened: California-based Kezar announced positive interim results from the Phase 2 portio...
Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...
Kezar Life Sciences to Present at the Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...
Oxford Finance Provides $50 Million Credit Facility to Kezar Life Sciences, Inc.
ALEXANDRIA, Va. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oxford Finance Provides $50 Million Credit Facility to Kezar Life Sciences, Inc.
Kezar Reports Third Quarter Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and ...
Kezar to Host Virtual Investor and Analyst Day on November 15, 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...
Kezar Announces First Patient Dosed in Phase 1 Trial of KZR-261 in Advanced Solid Tumor Malignancies
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...
Kezar Life Sciences Appoints Gitanjali Jain as Vice President, Investor Relations and External Affairs
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...
Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyosi...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...
Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business Updates
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and ...
Kezar Life Sciences to Participate in the William Blair Biotech Focus Conference 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...
Kezar Life Sciences Announces Formation of Clinical Advisory Committee
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...
Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...
Kezar Appoints Rheumatology Industry Expert, Micki Klearman, MD, to its Board of Directors
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...
Kezar Life Sciences to Participate in the Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...
Kezar Life Sciences to Host Virtual MISSION Phase 1b Data Update Call at EULAR 2021 on June 2, 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...
Kezar Life Sciences Reports First Quarter Financial Results and Provides Business Updates
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...
Kezar Life Sciences Recognized as 2021 Bay Area Best Places to Work
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...
Kezar Life Sciences Presents Preclinical Data with IND Candidate KZR-261 at American Association for Cancer Research ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncolo...
Kezar Life Sciences Reports Fourth Quarter and Year End 2020 Financial Results and Provides Business Updates
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...
Kezar Life Sciences to Participate at Cowen 41st Annual Virtual Health Care Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and on...
Kezar Life Sciences to Present at BIO CEO & Investor Digital Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and on...
Kezar Life Sciences: Targeting The Immunoproteasome To Treat Autoimmunity
Kezar is a founder-driven company with deep expertise in proteasome and drug development, and they have a track record of approved medicines. The company's lead asset, KZR-616, is a first-in-class inhib...